Literature DB >> 27636691

Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome.

Denise J Maguire1, Susan Taylor, Kathleen Armstrong, Emily Shaffer-Hudkins, Aaron M Germain, Sandra S Brooks, Genieveve J Cline, Leah Clark.   

Abstract

Parents of infants with neonatal abstinence syndrome (NAS) in the NICU may have questions about the long-term consequences of prenatal exposure to methadone, both asked and unasked. Although the signs of withdrawal will abate relatively quickly, parents should be aware of potential vision, motor, and behavioral/cognitive problems, as well as sleeping disturbances and ear infections so their infants can be followed closely and monitored by their pediatrician with appropriate referrals made. Furthermore, this knowledge may inspire parents to enroll their infants in an early intervention program to help optimize their outcomes. There are still many unanswered questions about epigenetic consequences, risk for child abuse/neglect, and risk of future substance abuse in this population.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27636691     DOI: 10.1891/0730-0832.35.5.277

Source DB:  PubMed          Journal:  Neonatal Netw        ISSN: 0730-0832


  27 in total

1.  Integrative Review of Gut Microbiota and Expression of Symptoms Associated With Neonatal Abstinence Syndrome.

Authors:  Stephanie D Sealschott; Rita H Pickler; Christine A Fortney; Michael T Bailey
Journal:  Nurs Res       Date:  2020 Sep/Oct       Impact factor: 2.381

2.  Opioid use disorder research and the Council for the Advancement of Nursing Science priority areas.

Authors:  Patricia Eckardt; Donald Bailey; Holli A DeVon; Cynthia Dougherty; Pamela Ginex; Cheryl A Krause-Parello; Rita H Pickler; Therese S Richmond; Eleanor Rivera; Carol F Roye; Nancy Redeker
Journal:  Nurs Outlook       Date:  2020-04-09       Impact factor: 3.250

3.  Methadone Versus Buprenorphine for Opioid Use Dependence and Risk of Neonatal Abstinence Syndrome.

Authors:  Lara S Lemon; Steve N Caritis; Raman Venkataramanan; Robert W Platt; Lisa M Bodnar
Journal:  Epidemiology       Date:  2018-03       Impact factor: 4.822

4.  Association between prenatal opioid exposure, neonatal opioid withdrawal syndrome, and neurodevelopmental and behavioral outcomes at 5-8 months of age.

Authors:  Ludmila N Bakhireva; Bradley D Holbrook; Shikhar Shrestha; Yuridia Leyva; Malia Ashley; Sandra Cano; Jean Lowe; Julia M Stephen; Lawrence Leeman
Journal:  Early Hum Dev       Date:  2018-12-13       Impact factor: 2.079

5.  Surveillance, Epidemiology, and Estimated Burden of Neonatal Abstinence Syndrome, Tennessee, 2013-2016.

Authors:  Julia Brennan; Caleb Wiedeman; John R Dunn; William Schaffner; Timothy F Jones
Journal:  Public Health Rep       Date:  2019-08-07       Impact factor: 2.792

Review 6.  Opioid Use in Pregnancy.

Authors:  Amalia Londono Tobon; Erin Habecker; Ariadna Forray
Journal:  Curr Psychiatry Rep       Date:  2019-11-16       Impact factor: 5.285

7.  Identification of neonatal abstinence syndrome in the community: Infants born into Canada's opioid crisis.

Authors:  Amanda Haas
Journal:  Paediatr Child Health       Date:  2018-08-14       Impact factor: 2.253

8.  The Role of Preterm Birth in the Association Between Opioid Maintenance Therapy and Neonatal Abstinence Syndrome.

Authors:  Lara S Lemon; Ashley Naimi; Steve N Caritis; Robert W Platt; Raman Venkataramanan; Lisa M Bodnar
Journal:  Paediatr Perinat Epidemiol       Date:  2018-01-26       Impact factor: 3.980

9.  Prenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes.

Authors:  Karol Kaltenbach; Kevin E O'Grady; Sarah H Heil; Amy L Salisbury; Mara G Coyle; Gabriele Fischer; Peter R Martin; Susan Stine; Hendrée E Jones
Journal:  Drug Alcohol Depend       Date:  2018-02-01       Impact factor: 4.492

10.  Well-Child Care Adherence After Intrauterine Opioid Exposure.

Authors:  Neera K Goyal; Jessica F Rohde; Vanessa Short; Stephen W Patrick; Diane Abatemarco; Esther K Chung
Journal:  Pediatrics       Date:  2020-01-02       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.